

~~Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.~~

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Complete if Known

RECEIVED

~~MAY 17 2001~~

TECH CENTER 1600/2900

Sheet

1

of

4

Attorney Docket Number

A-63470-7/RFT/JJD

U.S. PATENT DOCUMENTS

[illegible]

FOREIGN PATENT DOCUMENTS

[illegible]

**Examiner
Signature**

Daria A. Saunders

Date
Considered

8/8/0

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English Language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231.

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box → ☐

PTO/SB/8B (08-00)

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Complete if Known

Application Number	09/628,568
Filing Date	July 31, 2000
First Named Inventor	PRESTA, Leonard G.
Group Art Unit	1644
Examiner Name	
Attorney Docket Number	A-63470-7/RFT/JJD

RECEIVED

MAY 17 2001

TECH CENTER 1600/2900

Sheet 2 of 4

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
Das	6	Diegel, M.L. et al., "Regulation of HIV Production by Blood Mononuclear Cells from HIV-Infected Donors: II. HIV-1 Production Depends on T-Cell-Monocyte Interaction," AIDS Research and Human Retroviruses, 9(5):465-473 (1993).	
Das	7	Batra, J.K. et al., "Insertion of constant Region Domains of Human IgG.sub.1 Into CD4-PE40 Increases Its Plasma Half-Life," Molecular Immunology, 30(4):379-386 (1993).	
Das	8	Kim, J.-K. Et al., "Catabolism of the Murine IgG1 Molecule: Evidence that Both CH2-CH3 Domain Interfaces are Required for Persistence of IgG1 in the Circulation of Mice," Scand. J. Immunol., 40:457-465 (1994).	
Das	9	Traunecker et al., "Bispecific single chain molecules (Janusins) target cytotoxic lymphocytes on HIV infected cells," EMBO J. 10(12): 3655-3659 (1991).	
Das	10	Brambell, "The Transmission of Immunity from Mother to Young and the Catabolism of Immunoglobulins" Lancet pp. 1087-1093 (Nov. 19, 1966).	
Das	11	Brambell et al., "A Theoretical Model of .gamma.-Globulin Catabolism" Nature 203:1352-1355 (1964).	
Das	12	Deisenhofer, "Crystallographic Refinement and Atomic Models of a Human Fc fragment and Its Complex with Fragment B of Protein A from Staphylococcus aureus at 2.9- and 2.8-A Resolution" Biochemistry 20(9):2361-2370 (1981).	
Das	13	Dima et al., "Effect of protein A and its fragment B on the catabolic and Fc receptor sites of IgG" European Journal of Immunology 13:605-614 (1983).	
Das	14	Ellerson et al., "Isolation and Characterization of a Fragment Corresponding to the C.gamma. Homology Region of Human Immunoglobulin G.sup.1." Journal of Immunology 116(2):510-517 (Feb. 1976).	
Das	15	Kim et al., "Identifying amino acid residues that influence plasma clearance of murine IgGa fragments by site-directed mutagenesis" European Journal of Immunology 24:542-548 (1994).	
Das	16	Knauff et al., "Relationship of Effective Molecular Size to Systematic Clearance in Rats of Recombinant Interleukin-2 Chemically Modified with Water-soluble Polymers" Journal of Biological Chemistry 263:15064-15070 (1988).	

Examiner Signature	David G. Lander	Date Considered	8/9/01
--------------------	-----------------	-----------------	--------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English Language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box → ☐

PTO/SB/8B (08-00)

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)


Complete if Known

Application Number	09/628,568
Filing Date	July 31, 2000
First Named Inventor	PRESTA, Leonard G.
Group Art Unit	1644
Examiner Name	
Attorney Docket Number	A-63470-7/RFT/JJD

RECEIVED

MAY 17 2001

TECH CENTER 1600/2900



Sheet 3 of 4

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
dal	17	Masson, "Elimination of Infectious Antigens and Increase of IgG Catabolism as Possible Modes of Action of IVIg" Journal of Autoimmunity 6:683-689 (1993).	
dal	18	Nose et al., "Biological significance of carbohydrate chains on monoclonal antibodies" Proc. Natl. Acad. Sci. USA 80:6632-6636 (Nov. 1983).	
dal	19	Pollock et al., "Intravascular metabolism of normal and mutant mouse immunoglobulin molecules" European Journal of Immunology 20:2021-2027 (1990).	
dal	20	Spector, "The reabsorption of labelled proteins by the normal and nephrotic rat kidney" J. Path. Bact. 68:187-196 (1954).	
dal	21	Spiegelberg, "Biological Activities of Immunoglobulins of Different Classes and Subclasses" Advances in Immunology 19:259-294 (1974).	
dal	22	Spiegelberg et al., "The Catabolism of Homologous and Heterologous 7S Gamma Globulin Fragments" J. of Experimental Medicine, Dubos et al. vol. 121(1):323-338 (1965).	
dal	23	Tao et al., "Role of Carbohydrate in the Structure and Effector Functions Mediated by the Human IgG Constant Region" Journal of Immunology 143(8):2595-2601 (Oct. 15, 1989).	
dal	24	Waldmann et al., "Catabolism of Immunoglobulins" Progress in Immunology 1:1187-1191 (1971).	
dal	25	Wawrzyniczak et al., "Blood Clearance in the Rat of a Recombinant Mouse Monoclonal Antibody Lacking the N-Linked Oligosaccharide Side Chains of the C.sub.H 2 Domains" Molecular Immunology 29(2):213-220.	
dal	26	Wawrzyniczak et al., "Recombinant Mouse Monoclonal Antibodies with single Amino Acid Substitutions Affecting C1q and High Affinity Fc Receptor Binding Have Identical Serum Half-lives in the BALB/c Mouse" Molecular Immunology 29(2):221-227 (1992).	
dal	27	Wochner et al., "The Role of the Kidney in the Catabolism of Bence Jones Proteins and Immunoglobulin Fragments" Journal of Experimental Medicine 126(2):207-221 (Aug. 1, 1967).	

Examiner Signature	<i>David A. Henderson</i>	Date Considered	5/9/01
--------------------	---------------------------	-----------------	--------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English Language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box → ☐

PTO/SB/8B (08-00)

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Complete if Known

Application Number	09/628,568
Filing Date	July 31, 2000
First Named Inventor	PRESTA, Leonard G.
Group Art Unit	1644
Examiner Name	
Attorney Docket Number	A-63470-7/RFT/JJD

Sheet 4 of 4

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
JUL	28	Yasmeen et al., "The Distribution of effector Functions Among the C.gamma.2 and C.gamma.3 Homology Region Immunoglobulin G.sup.1 " Journal of Immunology 116(2):518-526 (Feb. 1976).	
JUL	29	Zuckier et al., "Immunologic and Pharmacologic Concepts of Monoclonal Antibodies" Seminars in Nuclear Medicine 19(3):166-186 (Jul. 1989).	
JUL	30	Zuckier et al., "The Use of Severe Combined Immunodeficiency Mice to Study the Metabolism of Human Immunoglobulin G" Cancer Supplement 73(3):794-799 (Feb. 1, 1994).	

Examiner Signature	Daniel A. Sauer	Date Considered	8/9/01
--------------------	-----------------	-----------------	--------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English Language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.